Trillium Therapeutics Inc (TSE:SSS) Director Gordon Edward Zelko bought 93,000 shares of the business’s stock in a transaction that occurred on Friday, July 7th. The shares were acquired at an average cost of C$0.11 per share, for a total transaction of C$10,230.00.

ILLEGAL ACTIVITY NOTICE: “Gordon Edward Zelko Buys 93,000 Shares of Trillium Therapeutics Inc (TSE:SSS) Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/10/gordon-edward-zelko-buys-93000-shares-of-trillium-therapeutics-inc-tsesss-stock.html.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc (TTI-621) program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1).

Insider Buying and Selling by Quarter for Trillium Therapeutics (TSE:SSS)

Receive News & Ratings for Trillium Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.